British Journal of Pharmacology
July 4, 2005
Alfred Richard Green, Esther O’shea, Kathryn S. Saadat et al.
70 citations
3,4‐Methylenedioxymethamphetamine (MDMA, ‘ecstasy’) administration to rats produces hyperthermia if they are housed in normal or warm ambient room temperature ( T a ) conditions (20°C), but hypothermia when in cool conditions ( T a 17°C). We have now investigated some of the mechanisms involved. MDMA (5 mg kg −1 i.p.) produced a rapid decrease in rectal temperature in rats at T a 15°C. This...
Revista de Neurología
July 1, 2005
[3,4-methylenedioxymethamphetamine ('ecstasy'): its long-term emotional and cognitive effects, and serotonin depletion].
Drug and Alcohol Review
July 1, 2005
Joachim D. Uys, Raymond J.m. Niesink
35 citations
Epidemiological studies show that the use of club drugs is on the rise. Furthermore, the last few decades have seen a rise in patterns of polydrug use. One of the combinations frequently used is ecstasy (MDMA) with gammahydroxybutyrate (GHB). For effective prevention it is important to be aware of this phenomenon and of the pharmacology of these drugs. The effects of the combination extend to...
Journal of Psychopharmacology
June 27, 2005
Franz X. Vollenweider, Matthias E. Liechti, Martin P. Paulus
24 citations
Decision-making, i.e. selecting an action from a number of alternatives when the outcome is uncertain, is a complex process that is important for everyday life. 3,4-Methylenedioxymethamphetamine (MDMA), also known as 'Ecstasy', is a widely used recreational drug that is known to increase serotonin (5-HT) and, to a lesser extent, dopamine (DA) in animals. This study examined whether MDMA alters...
Human psychopharmacology
June 2005
R M Milani, A C Parrott, F Schifano et al.
Cannabis is one of the most common 'co-drugs' for ecstasy users. The aim of the present study was to explore self-reported psychobiological problems in ecstasy polydrug users in relation to their pattern of cannabis use. Two hundred and eighty ecstasy polydrug users were allocated into five cannabis groups according to the frequency of their cannabis use. The control group comprised 121...
Critical Care Medicine
June 1, 2005
Jon E. Sprague, Petra Moze, David Caden et al.
75 citations
These data show that alpha1 and beta3-adrenergic receptors may contribute to the mediation of MDMA-induced hyperthermia and that drugs targeting these receptors, such as carvedilol, warrant further investigation as novel therapies for the treatment of psychostimulant-induced hyperthermia and its sequelae.
Psychopharmacology
May 2005
Matthew Rizzo, C T J Lamers, C G Sauer et al.
Illicit drug use can increase driver crash risk due to loss of control over vehicle trajectory. This study asks, does recreational use of +/-3,4-Methylenedioxymethamphetamine (MDMA; ecstasy) and tetrahydrocannabinol (THC; marijuana) impair cognitive processes that help direct our safe movement through the world? This study assesses the residual effects of combined MDMA/THC use, and of THC use...
Journal of Pharmacology and Experimental Therapeutics
April 2005
Douglas C. Jones, Christine L. Duvauchelle, Aiko Ikegami et al.
The selective serotonergic neurotoxicity of 3,4-methylenedioxyamphetamine (MDA) and 3,4-methylenedioxymethamphetamine (MDMA, ecstasy) depends on their systemic metabolism. We have recently shown that inhibition of brain endothelial cell gamma-glutamyl transpeptidase (gamma-GT) potentiates the neurotoxicity of both MDMA and MDA, indicating that metabolites that are substrates for this enzyme...
Brain Research
March 8, 2005
Alexander Freezer, Abdallah Salem, Rodney J. Irvine
34 citations
3,4-Methylenedioxymethamphetamine (MDMA, "ecstasy") and para-methoxyamphetamine (PMA) are commonly used recreational drugs. PMA, often mistaken for MDMA, is reported to be more toxic in human use than MDMA. Both of these drugs have been shown to facilitate the release and prevent the reuptake of 5-hydroxytryptamine (5-HT, serotonin). PMA is also a potent inhibitor of monoamine oxidase type A...
Behavioural Pharmacology
March 1, 2005
V. Buben Kov, Martin Votava, J. Hora Ek et al.
38 citations
Sensorimotor gating is the ability of a weak sensory event to inhibit the motor response to an intense stimulus. Drugs that act as serotonin releasers, such as MDMA (3,4-methylenedioxymethamphetamine), impair sensorimotor gating, which is measured as a prepulse inhibition (PPI) of the acoustic startle response. The first objective of the present study was to compare the effect of different...